Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)

US12214051B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Yuan Cheng · Newbury Park, US
• Chawita Netirojjanakul · Longmont, US
• Jerry Ryan HOLDER · Simi Valley, US
• Bin Wu · Thousand Oaks, US
• James R. Falsey · Moorpark, US
• Bradley J. Herberich · Newbury Park, US
• Kelvin Sham · Thousand Oaks, US
• Leslie P. Miranda · Thousand Oaks, US
• Shu Lu · Thousand Oaks, US
• Murielle M. Venient-Ellison · Thousand Oaks, US
• Shanaka Stanislaus · Thousand Oaks, US
• Junming Yie · Hackettstown, US
• Jing Xu · Beijing, CN

Key dates

• Filing date: Jan 15, 2021
• Grant date: Feb 4, 2025
• Expiry date: Jul 25, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/77
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.